Dow Jones

40 817,06

1,51%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Précédent 2 3 4 5 6 7 8 9 10 11 12 13 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
08/08/2005	15h01	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2005	21h28	PR Newswire (US)	Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/05/2005	00h46	PR Newswire (US)	Allos Therapeutics Announces Stockholder Approval of Share Exchange	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	15h00	PR Newswire (US)	Allos Therapeutics to Present at the Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2005	15h01	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/03/2005	12h00	PR Newswire (US)	Allos Therapeutics to Present at SG Cowen's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2005	12h02	PR Newswire (US)	Allos Therapeutics Reports 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2005	12h00	PR Newswire (US)	Allos Therapeutics Announces $50 Million Financing	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/01/2005	14h00	PR Newswire (US)	Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/01/2005	14h01	PR Newswire (US)	Allos Therapeutics Announces Expansion of ENRICH Trial Into Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/12/2004	14h00	PR Newswire (US)	Allos Therapeutics Licenses New Cancer Compound	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2004	17h38	PR Newswire (US)	Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Sympos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2004	12h00	PR Newswire (US)	Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/11/2004	14h01	PR Newswire (US)	Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2004	22h30	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2004	22h30	PR Newswire (US)	Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/10/2004	15h00	PR Newswire (US)	Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/10/2004	15h00	PR Newswire (US)	Allos Therapeutics to Present at Rodman & Renshaw Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2004	15h00	PR Newswire (US)	Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/10/2004	23h30	PR Newswire (US)	Response at Three-Months Post WBRT Found to be Statistically Significant Predictor of Survival in Largest Ever Randomized Study	NASDAQ:ALTH
04/10/2004	21h30	PR Newswire (US)	Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	22h23	PR Newswire (US)	Allos Therapeutics Receives Orphan Drug Designation From U.S. FDA for EFAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	14h45	PR Newswire (US)	Reminder - Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	13h00	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/07/2004	15h00	PR Newswire (US)	Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2004	15h01	PR Newswire (US)	Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/06/2004	15h00	PR Newswire (US)	Allos to Present at Needham and Company's Third Annual Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/06/2004	15h01	PR Newswire (US)	Data Presented at ASCO Demonstrate That Red Blood Cell Levels of Allos Therapeutics' RSR13 Correlate With Treatment Effect in Pa	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/06/2004	20h05	PR Newswire (US)	Data From Phase 3 Trial of Allos Therapeutics' RSR13 (efaproxiral) Presented at ASCO	NASDAQ:ALTH
06/06/2004	19h23	PR Newswire (US)	Analysis From Phase 3 Trial Suggests That Some Non-Small Cell Lung Cancer Patients With Brain Metastases May Benefit From Allos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)